MGMark Robert Gillrie

Mark Robert Gillrie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Robert Gillrie has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A vascularized human lung-on-a-chip reveals compartmentalized inflammatory responses in bacterial pneumonia

    by Kelsie Volek, Hellen Kang, Nicole Rosin, Mohammad Rehan, Theodore Nelson, Mortaza Fatehi-Hassanabad, Sarthak Sinha, Bryan Yipp, Jeff Biernaskie, Roger Kamm, et al.

    The lung serves as a primary organ for gas exchange in the human body. However, during clinically apparent lung insults such as bacterial pneumonia, the blood-alveolar barrier is disrupted, immune cells are recruited, and lung biomechanics are altered. These processes impair lung function acutely with major contributions from the lung vasculature. The pulmonary vasculature normally provides an 8km long vascular network interfacing with the 50-100m2 epithelial surface of the lung. This vasculature is a critical regulator of lung development, homeostasis, and function; yet to date, 3D organ-on-a-chip lung models have largely relied on planar vascular structures that do not recapitulate a true microvascular compartment. Here, we generate a human vascularized lung on a chip (LoC) containing a ventilated epithelial lined air-liquid interface surrounded by human lung fibroblasts and a functional microvascular network. We perform detailed transcriptomic, morphologic, and functional characterization of the LoC to demonstrate the physiologic relevance of this model and examine acute inflammation during bacterial pneumonia. Using scRNAseq we observe enhanced cellular differentiation, function, and crosstalk in LoC 3D co-culture. During bacterial infection with Streptococcus pneumoniae, the most common bacterial cause of human pneumonia, we identify a sequence of events where infection causes compartmentalized inflammatory responses and intravascular immune cell recruitment. This precedes complete air-blood barrier breakdown, tissue destruction associated with necroptotic cell death, and loss of tissue elasticity. Finally, using selective protease inhibitors we demonstrate a role for ADAM10 sheddase in driving neutrophil infiltration and epithelial dysfunction during pneumococcal pneumonia. This model provides a novel platform to mechanistically explore lung homeostasis and human lung diseases with potential for integration into existing human drug development pipelines.


  • Open Access

    Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R

    by Huu Tuan Nguyen, Nadia Gurvich, Mark Robert Gillrie, Giovanni Offeddu, Mouhita Humayun, Ellen L. Kan, Zhengpeng Wan, Mark Frederick Coughlin, Christie Zhang, Vivian Vu, et al.

    Tumor-associated inflammation drives cancer progression and therapy resistance, with the infiltration of monocyte-derived tumor-associated macrophages (TAMs) associated with poor prognosis in diverse cancers. Targeting TAMs holds potential against solid tumors, but effective immunotherapies require testing on immunocompetent human models prior to clinical trials. Here, we develop an in vitro model of microvascular networks that incorporates tumor spheroids or patient tissues. By perfusing the vasculature with human monocytes, we investigate monocyte trafficking into the tumor and evaluate immunotherapies targeting the human tumor microenvironment. Our findings demonstrate that macrophages in vascularized breast and lung tumor models can enhance monocyte recruitment via TAM-produced CCL7 and CCL2, mediated by CSF-1R. Additionally, we assess a novel multispecific antibody targeting CCR2, CSF-1R, and neutralizing TGF-β, referred to as CSF1R/CCR2/TGF-β Ab, on monocytes and macrophages using our 3D models. This antibody repolarizes TAMs towards an anti-tumoral M1-like phenotype, reduces monocyte chemoattractant protein secretion, and effectively blocks monocyte migration. Finally, we show that the CSF1R/CCR2/TGF-β Ab inhibits monocyte recruitment in patient-specific vascularized tumor models. Overall, this vascularized tumor model offers valuable insights into monocyte recruitment and enables functional testing of innovative therapeutic antibodies targeting TAMs in the tumor microenvironment (TME).


  • Open Access

    Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19

    by Sarthak Sinha, Nicole L. Rosin, Rohit Arora, Elodie Labit, Arzina Jaffer, Leslie Cao, Raquel Farias, Angela P. Nguyen, Luiz G. N. de Almeida, Antoine Dufour, et al.

    Although critical for host defense, innate immune cells are also pathologic drivers of acute respiratory distress syndrome (ARDS). Innate immune dynamics during Coronavirus Disease 2019 (COVID-19) ARDS, compared to ARDS from other respiratory pathogens, is unclear. Moreover, mechanisms underlying the beneficial effects of dexamethasone during severe COVID-19 remain elusive. Using single-cell RNA sequencing and plasma proteomics, we discovered that, compared to bacterial ARDS, COVID-19 was associated with expansion of distinct neutrophil states characterized by interferon (IFN) and prostaglandin signaling. Dexamethasone during severe COVID-19 affected circulating neutrophils, altered IFNactive neutrophils, downregulated interferon-stimulated genes and activated IL-1R2+ neutrophils. Dexamethasone also expanded immunosuppressive immature neutrophils and remodeled cellular interactions by changing neutrophils from information receivers into information providers. Male patients had higher proportions of IFNactive neutrophils and preferential steroid-induced immature neutrophil expansion, potentially affecting outcomes. Our single-cell atlas (see ‘Data availability’ section) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.


  • Open Access

    Risk Assessment of Hospitalized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Infected Patients Using Laboratory Data and Immune Cell Morphologic Assessment

    by Thane Kubik, Mary Hou, Tammie Traverse, Mlt Mireille Lareau, Veronika Jenei, Lisa Oberding, Dylan R. Pillai, Mark Gillrie, Deepa Suryanarayan, Davinder Singh Sidhu, et al.

    Context.—: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious agent, with the propensity to cause severe illness. While vaccine uptake has been increasing in recent months, many regions remain at risk of significant coronavirus disease 19 (COVID-19)–related health care burden. Health systems will continue to benefit from the availability of a variety of clinical and laboratory models when other triaging models are equivocal. Objective.—: To validate previously reported clinical laboratory abnormalities seen in COVID-19 patients and identify what laboratory parameters might be outcome predictive. Design.—: We undertook an observational study of hospital-admitted COVID-19 patients (n = 113), looking at a broad selection of clinical, laboratory, peripheral blood smear, and outcome data during discrete discovery and validation periods from March 2020 to November 2020. Results.—: We confirmed the findings of previous studies noting derangement of a variety of laboratory parameters in COVID-19 patients, including peripheral blood morphologic changes. We also devised a simple-to-use decision tree by which patients could be risk stratified on the basis of red blood cell count, creatinine, urea, and atypical plasmacytoid lymphocyte (“covidocyte”) count. This outcome classifier performed comparably to the World Health Organization clinical classifier and the neutrophil-lymphocyte ratio. Conclusions.—: Our data add to the increasing number of studies cataloguing laboratory changes in COVID-19 and support the clinical utility of incorporating blood morphologic assessment in the workup of hospitalized COVID-19 patients.


  • Dynamic interactions ofPlasmodiumspp. with vascular endothelium

    by Mark R. Gillrie, May Ho

    Plasmodial species are protozoan parasites that infect erythrocytes. As such, they are in close contact with microvascular endothelium for most of the life cycle in the mammalian host. The host-parasite interactions of this stage of the infection are responsible for the clinical manifestations of the disease that range from a mild febrile illness to severe and frequently fatal syndromes such as cerebral malaria and multi-organ failure. Plasmodium falciparum, the causative agent of the most severe form of malaria, is particularly predisposed to modulating endothelial function through either direct adhesion to endothelial receptor molecules, or by releasing potent host and parasite products that can stimulate endothelial activation and/or disrupt barrier function. In this review, we provide a critical analysis of the current clinical and laboratory evidence for endothelial dysfunction during severe P. falciparum malaria. Future investigations using state-of-the-art technologies such as mass cytometry and organs-on-chips to further delineate parasite-endothelial cell interactions are also discussed.